Vaso Corporation to sell wholly owned VasoHealthcare IT unit

Vaso Corporation reported that on November 19, 2025 it entered into an agreement to sell its wholly owned subsidiary, VasoHealthcare IT Corp. The announcement was made the same day through a press release, which is included as an exhibit to this report.

Rhea-AI Filing Summary

Vaso Corporation reported that on November 19, 2025 it entered into an agreement to sell its wholly owned subsidiary, VasoHealthcare IT Corp. The announcement was made the same day through a press release, which is included as an exhibit to this report. This move means Vaso plans to exit direct ownership of its healthcare IT subsidiary, though specific terms such as price, buyer, and closing conditions are not described in this excerpt.

8-K Event Classification

2 items: 8.01, 9.01

2 items

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Vaso Corporation (VASO) announce on November 19, 2025?

On November 19, 2025, Vaso Corporation announced that it had reached an agreement to sell its wholly owned subsidiary, VasoHealthcare IT Corp..

Which subsidiary is Vaso Corporation selling according to the 8-K filing?

Vaso Corporation is selling its wholly owned subsidiary VasoHealthcare IT Corp., as disclosed under Item 8.01 of the report.

How did Vaso Corporation communicate the sale of VasoHealthcare IT Corp.?

Vaso Corporation issued a press release dated November 19, 2025 announcing the sale of VasoHealthcare IT Corp., which is attached as Exhibit 99.1.

Is VasoHealthcare IT Corp. wholly owned by Vaso Corporation (VASO)?

Yes, the filing states that VasoHealthcare IT Corp. is a wholly owned subsidiary of Vaso Corporation.

Where can investors find more details on Vaso Corporation’s sale of VasoHealthcare IT Corp.?

More details are provided in the November 19, 2025 press release, which is attached to the report as Exhibit 99.1.

What exhibits are included with Vaso Corporation’s November 2025 8-K?

The report includes Exhibit 99.1, a November 19, 2025 press release, and Exhibit 104, the cover page interactive data file.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/20/2025 - 12:18 PM EST Learn about SEC filing dates

false 0000839087 0000839087 2025-11-19 2025-11-19 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 19, 2025

VASO CORPORATION

(Exact Name of Registrant as Specified in Charter)

Delaware		0-18105		11-2871434
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

137 Commercial St., Suite 200, Plainview, New York 11803

(Address of Principal Executive Offices and Zip Code)  

(516) 997-4600

Registrant’s Telephone Number, Including Area Code    

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class Trading Symbol(s) Name of Each Exchange on which Registered

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Exchange Act (17 CFR §240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01. Other Events

On November 19, 2025, Vaso Corporation announced its agreement to sell its wholly-owned subsidiary, VasoHealthcare IT Corp. A press release announcing the transaction is attached as Exhibit 99.1.

Item 9.01. Financial Statements and Exhibits

(d) Exhibits

99.1		November 19, 2025 Press Release
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

1

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: November 20, 2025

	VASO CORPORATION
	By:	/s/ Jun Ma
	Name:	Jun Ma
	Title:	Chief Executive Officer and President

2